UniProtKB/Swiss-Prot Q9UJ71: Variant p.Ala300Pro

C-type lectin domain family 4 member K
Gene: CD207
Feedback?

Variant information Variant position:

300 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Alanine (A) to Proline (P) at position 300 (A300P, p.Ala300Pro). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and hydrophobic (P) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

Significant reduction in mannose-binding ability; significant decrease in thermal stability; increased sensitivity of sugar binding to pH change. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs2080391 [ dbSNP | Ensembl ]

Sequence information Variant position:

300 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

328 The length of the canonical sequence.
Location on the sequence:

FWIPGEPNNAGNNEHCGNIK A PSLQAWNDAPCDKTFLFICK The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         FWIPGEPNNAGNNEHCGNIKAPSLQAWNDAPCDKTFLFICK

Mouse                         FWIPGEPNNAGNNEHCANIRVSALKCWNDGPCDNTFLFICK

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 328	C-type lectin domain family 4 member K
Topological domain	65 – 328	Extracellular
Domain	202 – 320	C-type lectin
Disulfide bond	223 – 319
Disulfide bond	295 – 311
Mutagenesis	285 – 285	E -> A. Loss of binding to 6'-sulfo-LacNAc and invertase.
Mutagenesis	287 – 287	N -> A. Loss of binding to 6'-sulfo-LacNAc and invertase.
Mutagenesis	299 – 299	K -> A. Loss of binding to 6'-sulfo-LacNAc.
Mutagenesis	313 – 313	K -> A. Loss of binding to 6'-sulfo-LacNAc and 6-sulfo-GlcNAc.
Beta strand	300 – 304

Literature citations
Polymorphisms in human langerin affect stability and sugar binding activity.
Ward E.M.; Stambach N.S.; Drickamer K.; Taylor M.E.;
J. Biol. Chem. 281:15450-15456(2006)
Cited for: VARIANTS ALA-278; ASP-288 AND PRO-300; CHARACTERIZATION OF VARIANT BIRGD ARG-264; CHARACTERIZATION OF VARIANTS ALA-278; ASP-288 AND PRO-300;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.